<span item_type="fundamental" item_id="700fcfcf645f192a29842053a0814a22" counter_id="ST/US/DMAAU" env="prod"></span><span item_type="announcement" item_id="518297578618814849" env="prod"></span><p>EPS: As of FY2025 Q1, the actual value is USD 0.05.</p><p></p><h3>Segment Revenue</h3><ul><li>The company has not commenced any operations and has not generated any operating revenues as of March 31, 2025. The company will generate non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025046061/ea0242665-10q_drugs.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Income</strong>: For the three months ended March 31, 2025, the company reported a net income of $1,254,543, primarily due to interest earned on cash and investments held in the Trust Account amounting to $1,585,468, offset by general and administrative costs of $330,925.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025046061/ea0242665-10q_drugs.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Operating Cash Flow</strong>: Net cash used in operating activities was - $251,244 for the three months ended March 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025046061/ea0242665-10q_drugs.htm"></span></li><li><strong>Investing Cash Flow</strong>: Net cash used in investing activities was - $231,150,000, primarily due to the investment of cash into the Trust Account.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025046061/ea0242665-10q_drugs.htm"></span></li><li><strong>Financing Cash Flow</strong>: Net cash provided by financing activities was $231,400,816, which includes proceeds from the sale of Units and Private Placement Units.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025046061/ea0242665-10q_drugs.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Cash and Investments Held in Trust Account</strong>: As of March 31, 2025, the company had $232,735,468 in cash and investments held in the Trust Account.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025046061/ea0242665-10q_drugs.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company intends to focus on companies in the pharmaceutical industry for its initial business combination. The company has 15 months from the closing of the Initial Public Offering to complete a Business Combination, with the possibility of extending this period up to 21 months.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025046061/ea0242665-10q_drugs.htm"></span></li><li><strong>Non-Core Business</strong>: The company has not identified any non-core business strategies or divestitures at this time.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025046061/ea0242665-10q_drugs.htm"></span></li></ul>

Drugs Made In America Acquisition - Unit | 10-Q: FY2025 Q1 EPS: USD 0.05